Zydus Reports Positive Phase 2b Saroglitazar MASH Data
Ahmedabad, Gujarat, India, and Pennington, New Jersey, USA, November 6, 2026 Zydus Therapeutics, Inc., a wholly owned subsidiary of...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Ahmedabad, Gujarat, India, and Pennington, New Jersey, USA, November 6, 2026 Zydus Therapeutics, Inc., a wholly owned subsidiary of...
LONDON, UK; SOLANA BEACH, California; and AHMEDABAD, India, August 11, 2026 Mereo BioPharma Group plc and Sentynl Therapeutics, Inc.,...
Ahmedabad, India / Pennington, New Jersey, August 4, 2026 Zydus Lifesciences Limited has received final approval from the U.S....
LAKE FOREST, Ill., June 16, 2026 Assertio Holdings, Inc. announced the successful completion of its previously announced merger with...
PENNINGTON, New Jersey and AHMEDABAD, India, May 28, 2026 Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences, has...
Zydus Therapeutics, Inc., a U.S.-based innovation arm of Zydus Lifesciences Ltd., today announced positive topline data from its pivotal...
